` EPIX (ESSA Pharma Inc) vs S&P 500 Comparison - Alpha Spread

EPIX
vs
S&P 500

Over the past 12 months, EPIX has underperformed S&P 500, delivering a return of -66% compared to the S&P 500's 9% growth.

Stocks Performance
EPIX vs S&P 500

Loading
EPIX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
EPIX vs S&P 500

Loading
EPIX
S&P 500
Difference
www.alphaspread.com

Performance By Year
EPIX vs S&P 500

Loading
EPIX
S&P 500
Add Stock

Competitors Performance
ESSA Pharma Inc vs Peers

S&P 500
EPIX
ABBV
AMGN
GILD
VRTX
Add Stock

ESSA Pharma Inc
Glance View

Market Cap
75m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
Not Available
Back to Top